Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer.

ABSTRACT:

Rationale

Recent studies have discovered several unique tumor response subgroups outside of response classification by Response Evaluation Criteria for Solid Tumors (RECIST), such as mixed response and oligometastasis. These subtypes have a distinctive property, lesion heterogeneity defined as diversity of tumor growth profiles in RECIST target lesions. Furthermore, many cancer clinical trials have been activated to evaluate various treatment options for heterogeneity-related subgroups (e.g., 29 trials so far listed in clinicaltrials.gov for cancer patients with oligometastasis). Some of the trials have shown survival benefit by tailored treatment strategies. This evidence presents the unmet need to incorporate lesion heterogeneity to improve RECIST response classification.

Meth

SUBMITTER: Chen DT 

PROVIDER: S-EPMC8248740 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature